Gene Signal [www.genesignal.com] based in Lausanne, Switzerland, have reported interim results of a randomized Phase II clinical study on their lead drug candidate, GS-101. The drug, an antisense oligonucleotide targeting a component of the VEGF pathway, is being used to treat corneal graft associated neovascularisation.